Tandem SNP-seq/FREP. SNP-seq detects SNPs that bind regulatory proteins to control cognate gene expression, using the capacity of type IIS restriction enzymes (for example, BpmI) to cleave DNA in a sequence-independent manner at a fixed distance to one side of the binding site ( Fig. 1a, top) . A 31-bp sequence containing each SNP is introduced into a double-stranded DNA construct, with the SNP itself positioned directly at the restriction enzyme cleavage site (Fig. 1a, bottom) . A library of constructs is incubated with nuclear extract from a disease-related cell population as a source of regulatory proteins. If a SNP binds a regulatory protein, it will be protected from restriction enzymes cleavage and amplified by PCR. Otherwise, it will be cut and negatively selected.
P olygenic diseases including juvenile idiopathic arthritis (JIA), rheumatoid arthritis, multiple sclerosis and type 1 diabetes arise through a complex interplay of genetic and environmental factors. Involvement of multiple alleles, each with modest impact, complicates genetic dissection of disease pathogenesis [1] [2] [3] .
Over the last 15 years, GWAS have enabled genetic exploration of polygenic diseases through the systematic identification of loci associated with disease risk. However, translation into mechanistic understanding has proven unexpectedly challenging. Most loci contain multiple variants, most commonly SNPs, each of which is potentially a functional SNP (fSNP). The search for fSNPs is complicated by the fact that most variants reside in noncoding regions, such as introns, 5′ and 3′ UTRs, or intergenic regions, and SNPs that alter protein coding are uncommon [4] [5] [6] . Bioinformatic and epigenetic analysis suggests that relatively few noncoding fSNPs alter canonical transcription factor binding sites 7 . Thus proceeding from GWAS to fSNP remains a challenge.
Recently, innovative strategies have been described to identify noncoding fSNPs. These include proteome-wide analysis of SNPs (PWAS) 8 ; bioinformatic enrichment using genetic, expression quantitative trait locus (eQTL) and epigenetic data 7, 9, 10 ; and massively parallel reporter assays (MPRAs) that test the translational impact of candidate SNPs [11] [12] [13] . These approaches each face limitations. PWAS is a SNP-by-SNP method that requires stable isotope labeling with amino acids in cell culture (SILAC), restricting the screen to cells grown in vitro. Epigenetic and eQTL data are specific for lineage and activation state. MPRAs reflect the transcriptional complement of model cells that can be transfected efficiently. Further, technical complexity places these methods beyond the range of most investigators. Thus there remains a need for complementary approaches that are amenable to a broad spectrum of cellular lineages while employing widely accessible methods.
SNP-sequencing (SNP-seq) employs restriction endonuclease protection, modified from the approach pioneered by Hardenbol and Van Dyke 14 , in an unbiased high-throughput experimental assay to identify fSNPs that bind regulatory proteins from an unrestricted range of input lineages. Application of flanking restriction enhanced pulldown (FREP) 15 then enables efficient identification of fSNP-bound regulatory proteins. Using tandem SNP-seq/FREP, we studied the CD40 locus, associated with rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus [16] [17] [18] [19] , and then applied the approach in a high-throughput manner across 608 SNPs associated with oligoarticular and seronegative polyarticular JIA 20 , enabling in each case the identification of previously unrecognized DNA-protein associations implicated by GWAS in human disease risk.
Once an fSNP is confirmed experimentally, identification of fSNP-bound proteins is accomplished using FREP 15 . In this method, the fSNP is employed as bait to pull down regulatory proteins from nuclear extract, reducing nonspecific binding through removal of both 5′ and 3′ DNA ends of the FREP construct via sequential restriction enzyme cleavage. For the present studies, FREP was modified by performance in parallel with an irrelevant control sequence to enable identification of differential protein binding by mass spectrometry (Fig. 1b ).
Identification of fSNPs at the CD40 locus.
To test SNP-seq, we first studied CD40. This locus contains 11 SNPs in linkage disequilibrium R 2 > 0.8, residing within ~17 kb of the 5′ promoter or within intron 1 (Fig. 2a) 21 . We engineered risk alleles from each SNP into independent SNP-seq constructs and incubated the 11-construct pool with nuclear extract from human BL2 B cells, followed by BpmI digestion and PCR amplification, repeating the procedure for 10 cycles. As a control, the construct pool was incubated without nuclear extract ( Fig. 2b ). PCR products from both experimental and control samples were cloned into TA vectors and sequenced by Sanger sequencing. The percentage of each SNP in the input (gray bar), experimental (red bar) and control (black bar) after mutated sequences were eliminated is shown in Fig. 2c . Relatively even numbers of reads for all sequences were observed in the input sample. However, SNPs rs4810485, rs6065926 and rs6032664 showed > 100% enrichment in experimental over control conditions, indicating strong protection from BpmI cutting and implicating these sites as candidate fSNPs (Fig. 2c ).
Validation of three fSNPs at the CD40 locus. To investigate whether rs4810485, rs6065926 and rs6032664 are fSNPs, we performed a luciferase reporter assay for all 11 SNPs. We cloned a 41-bp SNP-centered fragment containing either the risk or non-risk allele into the pGL3 vector (Promega) and transfected each reporter construct into THP-1, a CD40-expressing human monocyte cell line 22 , together with control vector pRL (Promega). While 8 of 11 SNPs showed no obvious allele-imbalanced luciferase activity, SNPs rs4810485, rs6065926 and rs6032664 exhibited a significant difference between alleles ( Fig. 3a) . These data indicate that the variants identified by SNP-seq are functional. In each case luciferase activity was lower for the risk allele, suggesting a negative regulatory role.
We next performed an electrophoretic mobility shift assay (EMSA) to assess allele-imbalanced nuclear protein binding, using 31-bp biotinylated DNA fragments centered on each SNP. These experiments confirmed allele-imbalanced gel shifts between the major or risk allele (lane 3) and minor or non-risk allele (lane 4) for all three candidate fSNPs, including specific competition using an unlabeled risk allele competitor (lane 5) ( Fig. 3b , red arrows).
To support the contention that these SNPs participate in the regulation of CD40, we employed CRISPR-Cas9 to perturb the associated sequences in BL2 cells. Three mutant clones were generated for rs4810485 (clones 1, 13 and 32; Fig. 3c , top) and two clones each for rs6032664 (clones 14 and 20; Fig. 3c , middle) and rs6065926 (clones 5 and 18; Fig. 3c , bottom). Wild-type (WT) and mutant sequences are listed in Fig. 3c (left). One clone at rs4810485 (clone 1) represented a homozygous mutation with the deletion of 1 bp and a 129-bp insertion, resulting in a CD40 truncation confirmed by western blot (Fig. 3c , middle). All mutants corresponding to the three fSNP sites showed significantly decreased CD40 protein and mRNA (Fig. 3c , middle and right). Together, these data validate the identification of rs4810485, rs6065926 and rs6032664 as noncoding fSNPs for CD40.
We compared SNP-seq findings with in silico analysis using HaploReg 4.1, a web-based tool for epigenetic and functional annotation of genetic variants 23 . We scored each of the 11 CD40 SNPs on a scale of 0 to 5 to reflect the number of positive annotations for histone methylation (two markers), DNase I hypersensitivity, predicted protein binding and predicted alteration in binding motifs: rs4810485 scored 5, rs6032664 scored 3, and rs6065926 scored 2, showing that SNP-seq identifies fSNPs not predicted by this method (Supplementary Table 1 ). Two SNPs in addition to rs4810485 scored 5 on the HaploReg scale and yet were not identified by SNP-seq: rs6074022 and rs1883832. Both have been implicated genetically in multiple sclerosis 24, 25 and were slightly enriched in the SNP-seq pool ( Fig. 2c) ; rs1883832 also exhibited a trend toward greater luciferase activity ( Fig. 3a ). We performed EMSA on these two SNPs, finding an allele-imbalanced gel shift for rs1883832 ( Supplementary Fig. 1 ). SNP-seq as applied to CD40 was therefore able to identify most but not all candidate noncoding fSNPs as determined by EMSA.
Identification of CD40 fSNP regulatory proteins by FREP.
To understand how the CD40 fSNPs identified by SNP-seq modulate gene expression, we performed FREP to define associated regulatory proteins. Pulldown using BL2 nuclear extract showed 1 protein associated specifically with rs4810485, 8 with rs6032664 and 15 with rs6065926 (Supplementary Table 2 ). Based on peptide spectrum count, we chose for further functional analysis RBPJ for rs4810485 (4 peptides in test vs. 0 in control), RSRC2 for rs6032664 (7 vs. 0), and FUBP1 and TRAP150 for rs6056926 (each 5 vs. 0). To investigate a potential function for these proteins, we performed knockdown experiments in BL2 cells. Using short hairpin RNA (shRNA) in the pRNAi-hU6-puro vector system (Biosettia), we identified three stable clones each for RBPJ (clones 4, 5 and 6) and FUBP1 (clones 11, 12 and 15) and two each for RSRC2 (clones 40, 46) and TRAP150 (clones 5 and 10) that showed reduced expression of their respective genes via western blot and real-time quantitative PCR (qPCR) (Fig. 4a ). Knocking-down each protein resulted in a significant increase in CD40 expression, consistent with our luciferase data, indicating a negative regulatory role for the three fSNPs.
To assess lineage specificity, we performed RNA interference (RNAi) knockdown in human synovial fibroblasts, a lineage that also expresses CD40 26 . To ensure that observed effects did not reflect incidental impact on the housekeeping reference gene, we employed short interfering RNAs (siRNAs) targeting sequences distinct from those in the BL2 studies, as well as a different transfection system, transient transfection via RNAi Max (Life Technologies). Consistent with the BL2 findings, knockdown of each gene upregulated CD40 expression in fibroblasts ( Fig. 4b ). Together, these results establish regulation of CD40 via three disease-associated fSNPs.
RBPJ and TRAP150 bind their associated fSNPs. To confirm that RBPJ and TRAP150 regulate CD40 expression via their corresponding SNPs, rs4810485 and rs6065926 respectively, we performed a gel supershift assay. Antibodies to RBPJ and TRAP150 yielded supershifted bands for RBPJ at rs4810485 and TRAP150 at rs6065926 ( Fig. 5a ). Multiple supershifted bands suggest binding to several distinct protein complexes containing RBPJ or TRAP150. Although we were unable to detect supershifted bands for RSRC2 and FUBP1, we did observe enhanced binding of these proteins to both rs6032664 and rs6065926, suggesting stabilization of the interaction of these proteins with their corresponding fSNPs ( Supplementary Fig. 2 ).
To validate endogenous binding of RBPJ to rs4810485 and TRAP150 to rs6065926, we performed chromatin immunoprecipitation (ChIP) with WT BL2 cells and shRNA knockdown clones (clone 5 for RBPJ and clone 5 for TRAP150; Fig. 4a ). For both RBPJ (top) and TRAP150 (bottom), we noted significant enrichment with RBPJ-or TRAP150-specific antibodies compared with control anti-immunoglobulin G (IgG) antibody, as well as between WT and shRNA knockdown BL2 cells ( Fig. 5b ). Together, these data demonstrate exogenous and endogenous binding of RBPJ to rs4810485 and TRAP150 to rs6065926.
In the process of generating mutations by CRISPR-Cas9 with a homologous sequence as a repair guide, we identified a heterozygous mutant clone with a G/T at rs4810485, instead of G/G in WT BL2 cells ( Fig. 5c ). Both flow cytometry and western blot showed downregulation of CD40, as predicted because the T is a non-risk allele (Fig. 5d,e ). We performed ChIP on this clone using anti-RBPJ and observed enrichment of rs4810485 compared to control anti-IgG ( Fig. 5f ). To confirm allele-imbalanced binding of RBPJ to the risk allele (G) versus the non-risk allele (T), we sequenced the rs4810485 DNA fragments from both input and ChIP samples by cloning into TA vectors. As predicted, a modest but statistically significant enrichment of the G allele was observed ( Fig. 5g ), supporting the allele specificity of the rs4810485 fSNP.
High-throughput screen with SNP-seq across 27 JIA loci. We next employed SNP-seq to screen 608 SNPs in linkage disequilibrium (R 2 > 0.8) with 27 loci associated with JIA 20 . In total, we screened 1,223 SNP-seq constructs representing both risk and non-risk alleles, including 7 SNPs with 3 alleles each. We generated the library through parallel oligonucleotide library synthesis (LC Sciences) and performed 10 cycles of SNP-seq using nuclear extract from healthy donor peripheral blood mononuclear cells as the source of regulatory proteins. Each cycle of SNP-seq was performed in duplicate, together with a control that consisted of constructs exposed to type IIS restriction enzyme cleavage in the absence of nuclear extract, to normalize for uneven input and for bias in PCR amplification. SNP sequences were quantified after 4, 7 and 10 cycles of enrichment using barcoded next-generation sequencing 27 . The resulting sequence data were analyzed as outlined ( Fig. 6a ). For quality control, we first selected only sequences containing 3′ BpmI binding sites with sequence 5′ -CTCCAG-3′ . The 5′ BpmI binding site is embedded in in the next-generation sequencing primer. This strategy ensures that we include only constructs that should have been cleaved by BpmI unless protected by binding proteins. Second, since transcription factors typically recognize 6-to 12-bp degenerate DNA sequences 28 , we selected only sequences in which 12 bp on either side of the target SNP corresponded accurately to the input SNP sequences, eliminating mutants arising during PCR amplification. Third, we eliminated SNPs for which complete sequence data were not available across cycles. We thereby ended up with a collection of 541 SNPs across all 27 loci. We normalized the read count at each allele by dividing the number of sequence reads for each replicate by the number of reads for that allele in the control (no nuclear extract), as diagrammed in Supplementary Figs. 3 and 4. Reproducibility was assessed by plotting these normalized values across replicates at cycle 10, finding a Pearson correlation coefficient r = 0.88 (P = 2.2 × 10 −16 ) ( Fig. 6b ).
To identify SNPs with allele-specific protection, we removed SNPs for which fewer sequence reads were detected at cycle 10 for each allele with nuclear extract than control, indicating lack of protection; SNPs eliminated at this stage included the seven SNPs with three alleles. We thereafter employed two parallel analytical approaches. First, we removed SNPs for which the difference in protection between the two alleles at cycle 10 was less than 20% ( Fig. 6a , left, and Supplementary Fig. 3 ), a proportion selected empirically from our experience screening the CD40 locus. We also eliminated SNPs for which replicates showed inconsistent results, defined as a ratio between replicates outside the range of 0.5 to 2.5, a range selected to recover SNPs from all loci. This curation left a set of 216 SNPs across 27 JIA loci. Second, we identified SNPs for which allelespecific protection increased with cycle number (Fig. 6a , right, and Supplementary Fig. 4 ), indicating progressive enrichment. For each SNP, and for each of the two replicates, we calculated the ratio of the normalized sequence count between alleles and fitted a linear model of the ratio across the three cycle points (cycles 4, 7 and 10) for each replicate. The slope of change with cycle number (β in the linear model) was termed the cycle point coefficient, and a P value was calculated comparing the observed coefficient to the null hypothesis of no change in allele ratio across cycles, without correction for multiple hypothesis testing. We retained only SNPs with an absolute value of cycle point coefficient > 0.03 and P values < 0.3 in both replicates, using R as per Methods. These coefficient and P cutoffs were determined by the elbow points in the empirical distributions (the point at which the change in slope was greatest). We eliminated SNPs for which replicate results were inconsistent, defined again for consistency as a ratio of cycle point coefficients outside the range of 0.5 to 2.5. In this way, we collected a second set of 229 SNPs across 26 JIA loci. We then merged the two sets of SNPs together to identify 148 candidate fSNPs across 25 JIA loci (Supplementary Table 3 ).
Characterization of fSNPs at the JIA-associated STAT4 locus.
To test our high-throughput screen, we selected one locus for more detailed characterization. SNP-seq identified four candidate fSNPs in the STAT4 locus, a region also implicated in rheumatoid arthritis and type 1 diabetes: rs11889341, rs4853459, rs8179673 and rs10181656 (Supplementary Table 3 ). Using EMSA with nuclear extract from Jurkat T cells, we confirmed allelic binding at rs8179673 and rs10181656 (Fig. 7a ). Both SNPs, 502 bp apart, are in intron 8 of STAT4, approximately 68 kb downstream of the STAT4 transcriptional start site. Neither SNP registered prominently by HaploReg 4.1 annotation (each 2 out of 5, in the midrange of all SNPs within the locus; Supplementary Table 4 ). Luciferase reporter assay indicated allele-dependent regulatory activity for both SNPs (Fig. 7b ). We then performed CRISPR-Cas9 to generate site mutations in Jurkat T cells. We obtained one mutant (clone 21) at rs8179673 and two (clones 13 and 14) at rs10181656 (Fig. 7c, left) . Western blot showed that these mutations significantly reduced STAT4 expression ( Fig. 7c, right) . We then performed FREP using Jurkat T cell nuclear extract, comparing each candidate fSNP with an irrelevant control (Supplementary Table 5 ). On the basis of peptide spectral count, we selected for further analysis H1.2 for rs10181656 (73 peptides vs. 0 in control) and SATB2 for rs8179673 (102 vs. 0). We then employed RNAi knockdown in Jurkat T cells using lentiviral particles (Santa Cruz, cat. no. sc-76456-V for SATB2 and sc-37970-V for H1.2). Knockdown of SATB2 induced STAT4 expression in Jurkat T cells, and H1.2 knockdown exhibited a similar trend (Fig. 7d) . We then performed RNAi knockdown in human synovial fibroblasts stimulated with IL-17 and TNFα 29 . Compared with control RNAi, we observed downregulation of STAT4 in SATB2 knockdown cells (Fig. 7e, left) but increased expression of STAT4 in H1.2 knockdown cells (Fig. 7e, right) , showing lineage-specific regulation of STAT4 via these two fSNPs.
To assess the overall accuracy of SNP-seq, we selected 14 candidate fSNPs at random from 9 additional JIA-associated loci. By EMSA, 11 of these showed allele-imbalanced gel shifts ( Supplementary Fig. 5 ). Together with the STAT4 locus (2 of 4 positive), these data indicate a true-positive rate greater than 70% (76% including the CD40 SNP-seq, a screen conducted using risk alleles only). We then performed EMSA on 7 SNPs at the STAT4 locus and 6 at the FAS locus that were not enriched by SNP-seq. We observed two clear positives at FAS, in addition to two borderline SNPs (one at each locus), a false negative rate of 15-31% (14-24% including CD40) ( Supplementary Fig. 6 ). Supplementary Figs. 2 and 3 . b, Correlation of the normalized sequence counts (count from sample treated with nuclear extract divided by count from control without nuclear extract) across two SNP-seq replicates (n = 2) at cycle 10 in 541 SNPs, plotted in log 2 transformation using R (see URLs) function "cor" and "cor.test" with the default setting using two-sided P value for Pearson correlation.
Discussion
GWAS launched a new era in the study of complex diseases by identifying numerous loci associated with disease risk. Most of these loci do not contain genetic variants that affect protein coding, implicating regulatory variants instead. Since many noncoding variants reside in linkage disequilibrium with each tagging SNP, GWAS by itself cannot define which variants are functional. We developed SNP-seq as a high-throughput experimental approach to identify polymorphisms that modulate the binding of regulatory proteins. Coupled with FREP 15 , SNP-seq enabled us to identify three fSNPs regulating CD40 via four regulatory proteins. Applying this approach genome-wide in JIA, SNP-seq identified 148 candidate fSNPs, including two that modulate STAT4 via previously unrecognized DNA-protein interactions. These observations suggest that tandem SNP-seq and FREP represents a useful strategy to identify new pathways of gene regulation, potentially opening the associated proteins to therapeutic targeting.
SNP-seq has both strengths and weaknesses. It is an unbiased high-throughput screen that can be performed across many SNPs simultaneously, testing risk and non-risk alleles in the same reaction to provide SNP-specific internal controls. As an experimental tool, SNP-seq avoids the probabilistic nature of in silico methods, while requiring in vitro techniques no more challenging than PCR. Because SNP-seq can be performed with any nuclear extract, it can be used to study primary cells, circumventing the lineage limitations intrinsic to SILAC proteomics and reporter assays based on cells maintained in culture. However, SNP-seq will detect only variants that modulate the binding of regulatory proteins, not those that alter protein coding or affect gene expression through splicing or regulatory RNA. Some protein-DNA interactions rely on the 3D structure of the DNA in addition to the recognition motif 30, 31 . As SNP-seq employs only a short synthetic DNA sequence, it will not detect fSNPs for which protein binding requires higher order structures or longer recognition sequences.
Importantly, SNP-seq will identify fSNPs only if the related regulatory proteins are in the nuclear extract tested. Results will therefore vary with lineage and with developmental or activation state. This limitation is counterbalanced by the ability to use any lineage or combination of lineages as the nuclear protein source. In many cases, the effect sizes of fSNPs and their associated proteins will be modest, as observed here, because the odds ratios for most GWAS loci are small (for example, 0.87 for CD40, 1.29 for STAT4) 16, 20 . Although SNP-seq can screen many loci at once, the number of SNPs that can be tested at once is limited by the number of quality reads that can be obtained across cycles. While we expect that the method can screen more than the 27 loci and 1,223 alleles tested simultaneously here, the maximum number that can be evaluated is unknown. Like other screening tools, SNP-seq is not completely accurate. Across 21 SNPs that identified as candidate fSNPs and characterized here by EMSA, more than 75% were positive. However, some fSNPs were missed, including rs1883832 at CD40, which had been implicated by HaploReg data and genetic association 24, 25 . Thus, while SNP-seq enables identification of candidate fSNPs, complementary approaches will be helpful, and detailed fSNP-by-fSNP validation remains essential.
Using SNP-seq and FREP, we identified RBPJ, RSRC2 and FUBP1/TRAP150 as regulatory proteins that control CD40. RBPJ is the main nuclear transducer of Notch signaling 32 . Its DNA binding consensus sequence is 5′ -[a/t]gTTCCCACg[g/c]t-3′ 33 , resembling the rs4810485 site 5′ -AGATTCC[G/T]GCC-3′ and suggesting that RBPJ may directly recognize this fSNP (capital letters refer to the highly-conserved recognition sequence and lower-case letters refer to more weakly conserved nucleotides). Of note, RBPJ has itself been implicated directly in rheumatoid arthritis and type 1 diabetes by GWAS and may be an autoantigen in multiple sclerosis [34] [35] [36] .
Less is known about the other proteins, although available data are intriguing. FUBP1 is a single-stranded DNA binding protein that activates the far upstream element (FUSE) to stimulate MYC expression 37 . TRAP150 is a transcriptional coactivator 38 . RSRC2 is implicated in cell proliferation 39 . We did not seek proteins engaging rs1883832, a candidate fSNP positive by EMSA but not identified by SNP-seq.
We reported previously that rheumatoid arthritis risk is associated with higher CD40 expression 21 . This conclusion is supported by our CRISPR-Cas9 data showing downregulation of CD40 with mutations at or around these fSNPs. Unexpectedly, luciferase studies showed lower activity for risk alleles at all three fSNPs, suggesting that they bind negative regulators. Similarly, RNAi knockdown of RBPJ, RSRC2 and FUBP1/TRAP150 enhanced CD40 expression in both BL2 cells and fibroblasts. This apparent paradox could reflect the known biology of RBPJ and FUBP1. In isolation, RBPJ is a transcriptional repressor. However, when bound to a coactivator such as Notch intracellular domain, released from Notch1 upon activation, it becomes a transcriptional activator 32 . Similarly, FUBP1 can either activate or repress transcription, modulated by proteins such as PUF60 40 . Lack of coactivators and/or expression of corepressors could explain how regulatory proteins enhance target expression in some contexts and reduce it in others. To test this hypothesis, we performed RNAi in fibroblasts to downregulate either Notch1 or PUF60. While no effect of Notch1 knockdown was noted, PUF60 knockdown significantly decreased CD40 expression ( Supplementary Fig. 7) . Further, chromosomal conformation capture (3 C) data suggested the presence of a DNA-protein complex that encompasses rs4810485, rs6032664 and rs6056926 ( Supplementary Fig. 8 ). How these fSNPs and their associated proteins regulate CD40 will be an important subject for future study.
JIA is a family of inflammatory arthritides that affects approximately 1 per 1,000 children 41 . SNP-seq identified 148 candidate fSNPs in 25 of 27 loci associated with JIA 20 . More stringent analytical conditions could have reduced the number of candidate fSNPs, at the expense of fewer loci covered. Validation studies at STAT4, a mediator of interleukin (IL)-12 and IL-23 signaling, confirmed two fSNPs. FREP identified a previously unknown interaction between rs8179673 and SATB2, a MAR binding protein 42 . The observed interaction is supported by the presence within rs8179673 of the MAR binding motif AAA[C/T]AAA 43 . SATB2 is a chromatin organizer that has been shown to bind and activate the immunoglobulin heavy chain enhancer 44 . For rs8179673, FREP identified an interaction with H1.2, a regulator of higher order chromatin structure mutated in germinal center B cell lymphomas 45 . Both fSNPs are 68 kb away from the transcriptional start site of STAT4, suggesting long-range chromatin effects. How SATB2 and H1.2 act via JIA-associated fSNPs to modulate arthritis risk remains to be established.
Collectively, these data show that SNP-seq and FREP represent a promising approach to translating GWAS data into molecular insight. Both CD40 and STAT4 are modulated by more than one fSNP, highlighting the complexity of genetic regulation. Areas for future exploration include target enrichment with complementary bioinformatic strategies and use of distinct nuclear extracts to explore the lineage specificity of GWAS risk loci. Together with other approaches, tandem SNP-seq and FREP could accelerate the understanding of human disease pathogenesis through populationlevel genetics.
URLs. 3 C protocol, http://www.epigenesys.eu/images/stories/protocols/pdf/20111025155834_p31.pdf; Fig. 6b , https://cran.r-project. org/, version 3.4.1.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0159-z.
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